CIK 0001720893 · Non-accelerated filer<br>Smaller reporting company
BioXcel Therapeutics, Inc.
Sign in to watch- Ticker
- BTAIQ
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 821386754
- Phone
- 203-643-8060
- Business address
- 555 LONG WHARF DRIVE, NEW HAVEN, CT, 06511
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 33 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-01-17 | Wiley Matthew T. CHIEF COMMERCIAL OFFICER | Grant or award · Stock Option (Right to Buy) | +85,000 | 85,000 | ||
| 2021-08-16 | Rodriguez Javier See Remarks | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2021-08-16 | Kane William P Jr Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2021-06-25 | Mehta Vimal CEO, President and Secretary | Sale | −473,250 | $30.83 | $14.6M | 8,546,750 |
| 2021-06-25 | Nandabalan Krishnan Director | Sale | −473,250 | $30.83 | $14.6M | 8,546,750 |
| 2021-06-25 | BioXcel LLC 10% owner | Sale | −473,250 | $30.83 | $14.6M | 8,546,750 |
| 2021-06-25 | BioXcel Holdings, Inc. 10% owner | Sale | −473,250 | $30.83 | $14.6M | 8,546,750 |
| 2021-06-11 | Laumas Sandeep Director | Grant or award · Stock Option (Right to Buy) | +14,500 | 14,500 | ||
| 2021-06-11 | Votruba Michal Director | Grant or award · Stock Option (Right to Buy) | +14,500 | 14,500 | ||
| 2021-06-11 | Votruba Michal Director | Other disposition · Stock Option (Right to Buy) | −14,500 | 0 | ||
| 2021-06-11 | MUELLER PETER Director | Grant or award · Stock Option (Right to Buy) | +14,500 | 14,500 | ||
| 2021-06-11 | Bray June Director | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2021-03-25 | O'Neill Vincent Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2021-03-25 | Yocca Frank Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2021-03-25 | Steinhart Richard I Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2021-03-25 | Mehta Vimal CEO, President and Secretary | Grant or award · Stock Option (Right to Buy) | +250,000 | 250,000 | ||
| 2021-03-15 | Yocca Frank Chief Scientific Officer | Sale | −14,370 | $48.47 | $697K | 59,027 |
| 2021-03-15 | Yocca Frank Chief Scientific Officer | Sale | −630 | $49.30 | $31K | 58,397 |
| 2021-03-01 | Bray June Director | Grant or award · Stock Option (Right to Buy) | +4,167 | 4,167 | ||
| 2021-02-22 | Rodriguez Javier See Remarks | Grant or award · Stock Option (Right to Buy) | +32,000 | 32,000 |
Page 23 of 27 · 521 trades